“Omeros reported 3Q18 with $4.6M in Omidria revenues, up from $1.7M in 2Q18. Omeros reported a net loss for the quarter of ($39.5M), and a cash balance of $55M, excluding the $210M debt offering announced concurrently. OMER shares are down ~20%, in our view, due to a misunderstanding of the financing.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 5.3% and a 40.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros Corp with a $28.67 average price target.
The company has a one-year high of $27 and a one-year low of $8.36. Currently, Omeros Corp has an average volume of 841.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.